Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 995 | 1045 | 1026 | 1131 | 1174 | 1479 |
Fund Return | -0.45% | 4.54% | 2.56% | 4.18% | 3.25% | 3.99% |
Place in category | 165 | 108 | 114 | 462 | 391 | 246 |
% in Category | 20 | 15 | 14 | 86 | 88 | 73 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
UK Equity Income Fund Institutional | 91.74M | 3.18 | 14.01 | 7.17 | ||
UK Equity Income Fund Retail Income | 141.62M | 3.04 | 13.40 | 6.57 | ||
UK Equity Income Fund Retail Accumu | 119.1M | -2.34 | 7.02 | 4.92 | ||
UK Equity Income Fund Z Accumulatio | 774.05M | -2.21 | 7.86 | 5.74 | ||
UK Equity Income Fund Z Income GBP | 693.53M | -2.20 | 7.86 | 5.75 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Index Unit Trust Accumulation | 13.44B | -0.70 | 7.90 | 5.03 | ||
All Share Index Unit Trust Income | 13.44B | 3.56 | 13.74 | - | ||
VG UK Plus GBP Accumulation | 13.44B | 3.56 | 13.76 | - | ||
VG UK Institutional Plus GBP Income | 13.44B | 3.56 | 13.75 | - | ||
UK Equity Tracker Fund D Acc | 10.79B | -0.91 | 7.84 | 5.18 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Shell | GB00BP6MXD84 | 7.04 | 30.96 | +0.85% | |
AstraZeneca | GB0009895292 | 5.30 | 10,678.0 | -0.60% | |
Relx | GB00B2B0DG97 | 5.04 | 3,424.00 | -0.09% | |
Unilever | GB00B10RZP78 | 4.01 | 46.52 | +0.54% | |
GSK plc | GB00BN7SWP63 | 3.81 | 1,708.60 | +0.20% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Strong Buy | Buy | Buy |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy |
Summary | Strong Buy | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review